1. GSK allies with Innovax for COVID-19 vaccine R&D project— Zentalis Pharma raises $165M in IPO — Drug discovery in the age of coronavirus — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Gilead to cut 1/5 of sales force

Discussion in 'Gilead Sciences' started by anonymous, Apr 10, 2019 at 4:17 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Word getting back to me is year end "right sizing".
     

  2. anonymous

    anonymous Guest

    Like the man said, $hit is going down beginning of 2020.
     
  3. anonymous

    anonymous Guest

    Just heard with new agreement Gilead will be expanding sales in 2020 and dat’s da word on da street!
     
  4. anonymous

    anonymous Guest

    Last post is FOS!! We are NOT expanding! Nice try. That's the final word!
     
  5. anonymous

    anonymous Guest

    Gilead aquired a European pipeline because its own lacked innovation.
    Gilead's stock has sank because all HIV competitors have caught up on the treatmen and prep side.
    J&J's HIV Vaccine would completely crush gilead if they dont do more things than HIV ASAP!
     
  6. anonymous

    anonymous Guest

    Hiring 4 EXEC DIR and 21 RDs for INFLAM
     
  7. anonymous

    anonymous Guest

    Also heard that company mandated 50% of salesforce has to be outside hires and not transfers. Complete bullshit!
     
  8. anonymous

    anonymous Guest

    If you want to work in a swamp of a market, go for rheum. As bad as oncology without any access.
     
  9. anonymous

    anonymous Guest

    So not likely I will hear back from my oncology application?
     
  10. anonymous

    anonymous Guest

    No it is not BS! We need to bring in fresh talent and get rid of under performers. Sorry but this is Business 101. If you are not a star performer, you best be looking for new employment.
     
  11. anonymous

    anonymous Guest



    Why would a star performer go to Gilead? Company has concrete boots on. Limited pipeline, layoffs ahead..I would have to question any star performer's desire to make a move to the Titanic.
     
  12. anonymous

    anonymous Guest

    Good sign on stock grant, above average pay, employee stock purchase plan, decent 401k match.

    Yes pipeline is limited but sitting on over 50 billion in cash which can purchase a pipeline.
     
  13. anonymous

    anonymous Guest

    How are you determining if someone is an "underperformer" in pharma sales. Haha how long have you been in the industry. Yes some of our reps suck but has little to do with rankings to determine who is underperforming. Of course we will- and should- take care of our own and move people over to this new division. That said Rheumatology is a very tough market- completely different than Hep C, Cardio or HIV which is much more primary care than specialty. Rheumatology is a true speciality market up and down- access, SP involvement, and knowledge about disease state/product. Much closer to Oncology. Not every rep will have the ability and know how to be able to make the jump.
     
  14. anonymous

    anonymous Guest

    underperforming rep is defined by bottom 25% by market share performance.
     
  15. anonymous

    anonymous Guest

    What type of market share? In HIV, it consists of Desi, even though all of us have only sold Biktarvy for nearly 2 years now.

    Market share also has no relationship to Quota attainment, as goals are set by some random person in Foster City.
     
  16. anonymous

    anonymous Guest

    Keep drinking that red Kool Aid. When the stock is $40 and blood flows in streets of Foster City you will wish you left for a place where sanity reigns and the only thing that matters is performance.

    and besides, Gilead has $30 BIL in cash. Still a lot but not 50...
     
  17. anonymous

    anonymous Guest

    $40 a share ain’t happening- they’d be bought out well before a price drop of that magnitude. I think they’re close right now. I’m actually hoping for it so I can cash out before they cure HIV.

    and yes, it’s ONLY 30 billion and growing.
     
  18. anonymous

    anonymous Guest

    I wish someone would buy us at a nice premium. But probably isn't going to happen. We have a ton of cash- hopefully we make some improvements on our pipeline.

    I heard same thing- 50% is goal for outside hires for new JAK. Management team being hired now. Not sure if we currently have the right leadership team in place. Going to be a dogfight to gain entry into that market since we will be last to market. Good data though but Abbvie drug has same selling points. Lilly JAK complete failure. Pfizer JAK is a blockbuster if we can get to that level would be huge success. Pfizer has black box warning- we will probably not.
     
  19. anonymous

    anonymous Guest


    Well, this seems to be true since my good friend who’s an RD just got a call to interview. He’s going to pursue it to get as much info as he can to share with me, but I doubt he will even consider since he’s with competitor and in a great spot. Not to mention, his salary is 225k so I’d be shocked if our HR dept will pay more than that.
     
  20. anonymous

    anonymous Guest

    $225k you say??? VPs might make that at Gilead, no one in the field ever will. Cheap ass hats